Immatics (NASDAQ:IMTX) Director Perceptive Advisors Llc Buys 863,060 Shares

Immatics N.V. (NASDAQ:IMTX) Director Perceptive Advisors Llc bought 863,060 shares of the stock in a transaction on Wednesday, August 26th. The shares were acquired at an average cost of $8.69 per share, for a total transaction of $7,499,991.40. Following the acquisition, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immatics Price Performance

Shares of NASDAQ:IMTX opened at $9.36 on Friday. The company has a market cap of $1.25 billion, a price-to-earnings ratio of -5.03 and a beta of 1.33. Immatics N.V. has a one year low of $5.05 and a one year high of $12.41. The firm has a fifty day moving average price of $9.45 and a two-hundred day moving average price of $10.04.

Immatics (NASDAQ:IMTX) last announced its earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.06). Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. The company had revenue of $10.44 million for the quarter, compared to the consensus estimate of $12.42 million. Equities research analysts expect that Immatics N.V. will post -2 EPS for the current fiscal year.

Analyst Ratings Changes

IMTX has been the topic of a number of research reports. Jefferies Financial Group set a $17.00 target price on shares of Immatics in a research note on Tuesday. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of Immatics in a research note on Tuesday, May 19th. Wall Street Zen cut Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Weiss Ratings lowered Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Immatics has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

Institutional Trading of Immatics

A number of large investors have recently added to or reduced their stakes in IMTX. Bank of America Corp DE lifted its position in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Immatics by 31.5% during the second quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock valued at $1,069,000 after buying an additional 47,590 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Immatics by 105.2% during the second quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock valued at $420,000 after buying an additional 40,058 shares during the last quarter. Engineers Gate Manager LP bought a new stake in shares of Immatics during the 2nd quarter worth approximately $124,000. Finally, Sofinnova Investments Inc. boosted its holdings in Immatics by 44.1% during the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock valued at $12,054,000 after acquiring an additional 686,224 shares during the period. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.